Андрогенная алопеция и коронавирусная инфекция

Мельниченко О.О., Сакания Л.Р., Пирузян А.Л., Корсунская И.М. Андрогенная алопеция и коронавирусная инфекция. Consilium Medicum. 2021; 23 (8): 617–620. DOI: 10.26442/20751753.2021.8.201086

________________________________________________

Melnichenko OО, Sakaniya LR, Piruzyan AL, Korsunskaya IM. Androgenetic alopecia and coronavirus infection. Consilium Medicum. 2021; 23 (8): 617–620. DOI: 10.26442/20751753.2021.8.201086

Читать PDF

Аннотация

Андрогенная алопеция (АА) – это нерубцовая потеря волос у мужчин и женщин, вызванная действием андрогенов на волосяные фолликулы и возникающая у лиц с генетической предрасположенностью. Заболевание носит хронический прогрессирующий характер и охватывает миллионы людей во всем мире. Методы лечения АА ограничены, а понимание патофизиологии, лежащей в основе заболевания, все еще развивается. Наряду с генетической преддиспозицией и сложными биохимическими процессами, происходящими в клетках волосяного сосочка, широко обсуждается роль новой коронавирусной инфекции COVID-19 в развитии АА. Сведения об эпидемиологии, клинических проявлениях, профилактике и лечении коронавирусной инфекции COVID-19 в настоящее время постоянно обновляются. Описаны клинические проявления COVID-19 на коже, включающие ангииты, акродерматит (акроангиит), папуловезикулезные высыпания, папулосквамозные высыпания, розовый лишай, кореподобную сыпь, токсикодермию, обострение хронических дерматозов, артифициальные поражения кожи и, наконец, выпадение волос. Ряд исследований демонстрирует связь между андрогенами, участвующими в патогенезе COVID-19, и возможным развитием АА.

Ключевые слова: андорогенная алопеция, COVID-19, дигидротестостерон, миноксидил, андрогены

________________________________________________

Androgenetic alopecia (AA) is a non-scarring hair loss in men and women caused by the effect of androgens on hair follicles which occurs in genetically predisposed individuals. The disease has chronic and progressive course and affects millions of people worldwide. AA treatments are limited, and understanding of the underlying pathophysiology is still is developing. Along with genetic predisposition and complex biochemical processes occurring in hair follicle cells, the role of new novel coronavirus infection COVID-19 in AA is widely discussed. Today, information on the epidemiology, clinical manifestations, prevention and treatment of coronavirus infection COVID-19 is constantly being updated. COVID-19-associated cutaneous manifestations have been described, including angiitis, acrodermatitis (acroangiitis), papular-vesicular eruptions, papular-squamous eruptions, pityriasis rosea, measles-like rash, toxicoderma, exacerbation of chronic dermatoses, artifactual skin lesions and, finally, hair loss. A number of studies demonstrate a link between androgens involved in the pathogenesis of COVID-19 and the possible occurrence of AA.

Keywords: androgenetic alopecia, COVID-19, dihydrotestosterone, minoxidil, androgens

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020;33(5):e13549. DOI:10.1111/dth.13549
2. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-3. DOI:10.1111/jdv.16387
3. Mungmungpuntipantip R, Wiwanitkit V. COVID-19 and cutaneous manifestations. J Eur Acad Dermatol Venereol. 2020;34(6):e246. DOI:10.1111/jdv.16483
4. Lei Y, Huang X, Bamu S, et al. Clinical features of imported cases of coronavirus disease 2019 in Tibetan patients in the plateau area. Infect Dis Poverty. 2020. DOI:10.21203/rs.3.rs-22978/v1
5. Freeman EE, McMahon DE, Fitzgerald ME, Fox LP. The AAD COVID-19 registry: crowdsourcing dermatology in the age of COVID-19. J Am Acad Dermatol. 2020;83(2):509-10. DOI:10.1016/j.jaad.2020.04.045
6. Клиническая характеристика кожных проявлений при новой коронавирусной инфекции COVID-19, вызванной SARS-CoV-2. ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии ДЗМ», ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России», ФГАОУ ВО «Российский университет дружбы народов Минобрнауки России». М., 2020 [Clinical characteristics of skin manifestations in the new coronavirus infection COVID-19 caused by SARS-CoV-2. Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Pirogov Russian National Research Medical University, Peoples’ Friendship University. Moscow, 2020 (in Russian)].
7. Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 2013;11(4):e9860. PMID: 24719635.
8. Hong H, Ji JH, Lee Y, et al. Reliability of the pattern hair loss classifications: a comparison of the basic and specific and Norwood-Hamilton classifications. J Dermatol. 2013;40(2):102-6. DOI:10.1111/1346-8138.12024
9. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:237-54.
10. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1-2):89-95. PMID: 12573818.
11. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296-300. PMID: 9284093.
12. Hamada K, Randall VA. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol. 2006;154(4):609-18. DOI:10.1111/j.1365-2133.2006.07144.x
13. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271.e8-280.e8.
14. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577-83. DOI:10.1002/jmv.25757
15. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
16. Wambier CG, Vano-Galvan S, McCoy J, et al. Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign”. J Am Acad Dermatol. 2020;69:680-2.
17. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol. 2020;31(8):1040-5. DOI:10.1016/j.annonc.2020.04.479
18. Bahmad HF, Abou-Kheir W. Crosstalk between COVID-19 and prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):561-3. DOI:10.1038/s41391-020-0262-y
19. Müller Ramos P, Ianhez M, Amante Miot H. Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020;29:1250-2. DOI:10.1111/exd.14220
20. ElFaramawy AAA, Hanna IS, Darweesh RM, et al. The degree of hair graying as an independent risk marker for coronary artery disease, a CT coronary angiography study. Egypt Heart J. 2018;70:15-9.
21. Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: a meta-analysis. Int J Cardiol. 2014;176:687-95.
22. Сакания Л.Р., Мельниченко О.О., Корсунская И.М. Потеря волос на фоне новой коронавирусной инфекции: подходы к лечению. Медицинский совет. 2021;8:77-80 [Sakaniia LR, Mel’nichenko OO, Korsunskaia IM. Poteria volos na fone novoi koronavirusnoi infektsii: podkhody k lecheniiu. Meditsinskii sovet. 2021;8:77-80 (in Russian)]. DOI:10.21518/2079-701X-2021-8-77-80
23. Мильдзихова Д.Р., Мельниченко О.О., Корсунская И.М. Современные подходы к терапии андрогенетической алопеции. Клиническая дерматология и венерология. 2019;18(4):501-4 [Mil’dzikhova DR, Mel’nichenko OO, Korsunskaia IM. Sovremennye podkhody k terapii androgeneticheskoi alopetsii. Klinicheskaia dermatologiia i venerologiia. 2019;18(4):501-4 (in Russian)]. DOI:10.17116/klinderma201918041501

________________________________________________

1. Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020;33(5):e13549. DOI:10.1111/dth.13549
2. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-3. DOI:10.1111/jdv.16387
3. Mungmungpuntipantip R, Wiwanitkit V. COVID-19 and cutaneous manifestations. J Eur Acad Dermatol Venereol. 2020;34(6):e246. DOI:10.1111/jdv.16483
4. Lei Y, Huang X, Bamu S, et al. Clinical features of imported cases of coronavirus disease 2019 in Tibetan patients in the plateau area. Infect Dis Poverty. 2020. DOI:10.21203/rs.3.rs-22978/v1
5. Freeman EE, McMahon DE, Fitzgerald ME, Fox LP. The AAD COVID-19 registry: crowdsourcing dermatology in the age of COVID-19. J Am Acad Dermatol. 2020;83(2):509-10. DOI:10.1016/j.jaad.2020.04.045
6. Clinical characteristics of skin manifestations in the new coronavirus infection COVID-19 caused by SARS-CoV-2. Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Pirogov Russian National Research Medical University, Peoples’ Friendship University. Moscow, 2020 (in Russian).
7. Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 2013;11(4):e9860. PMID: 24719635.
8. Hong H, Ji JH, Lee Y, et al. Reliability of the pattern hair loss classifications: a comparison of the basic and specific and Norwood-Hamilton classifications. J Dermatol. 2013;40(2):102-6. DOI:10.1111/1346-8138.12024
9. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:237-54.
10. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1-2):89-95. PMID: 12573818.
11. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296-300. PMID: 9284093.
12. Hamada K, Randall VA. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol. 2006;154(4):609-18. DOI:10.1111/j.1365-2133.2006.07144.x
13. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271.e8-280.e8.
14. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577-83. DOI:10.1002/jmv.25757
15. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
16. Wambier CG, Vano-Galvan S, McCoy J, et al. Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign”. J Am Acad Dermatol. 2020;69:680-2.
17. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol. 2020;31(8):1040-5. DOI:10.1016/j.annonc.2020.04.479
18. Bahmad HF, Abou-Kheir W. Crosstalk between COVID-19 and prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):561-3. DOI:10.1038/s41391-020-0262-y
19. Müller Ramos P, Ianhez M, Amante Miot H. Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020;29:1250-2. DOI:10.1111/exd.14220
20. ElFaramawy AAA, Hanna IS, Darweesh RM, et al. The degree of hair graying as an independent risk marker for coronary artery disease, a CT coronary angiography study. Egypt Heart J. 2018;70:15-9.
21. Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: a meta-analysis. Int J Cardiol. 2014;176:687-95.
22. Sakaniia LR, Mel’nichenko OO, Korsunskaia IM. Poteria volos na fone novoi koronavirusnoi infektsii: podkhody k lecheniiu. Meditsinskii sovet. 2021;8:77-80 (in Russian). DOI:10.21518/2079-701X-2021-8-77-80
23. Mil’dzikhova DR, Mel’nichenko OO, Korsunskaia IM. Sovremennye podkhody k terapii androgeneticheskoi alopetsii. Klinicheskaia dermatologiia i venerologiia. 2019;18(4):501-4 (in Russian). DOI:10.17116/klinderma201918041501

Авторы

О.О. Мельниченко*1, Л.Р. Сакания1,2, А.Л. Пирузян2, И.М. Корсунская1,2

1 ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия
*dr.melnichenko@gmail.com

________________________________________________

Olga О. Melnichenko*1, Luiza R. Sakaniya1,2, Anastas L. Piruzyan2, Irina M. Korsunskaya1,2

1 Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Moscow, Russia;
2 Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
*dr.melnichenko@gmail.com

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.